ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunotherapy - Pre-op, Post-op or No-op? NADINA Trial Discussion"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunotherapy - Pre-op, Post-op or No-op? NADINA Trial Discussion"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Harriet Kluger

123 views

June 10, 2024

Chapters

Overview & NADINA Trial Introduction

00:00

Neoadjuvant vs. Adjuvant Therapy Comparison

00:59

Event-Free Survival & Treatment Rationale

01:51

Adjuvant Therapy Evolution & Current Options

04:28

Immune-Related Adverse Events & Quality of Life

07:42

Comments 0

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical Outcomes…

2024 ASCO® Annual Meeting Insights Hub

L. Burton

129 views

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

771 views

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

326 views

View All

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

Advances in the Treatment of Melanoma

Masterclasses in Dermatology

D. Fisher

808 views

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

771 views

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

290 views

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Stanford Medicine

A. Betof Warner

1.0K views

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

713 views

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

478 views

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

523 views

ASCO® 2024 Summary: "Insights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

O. Hamid

463 views

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

2024 ASCO® Annual Meeting Insights Hub

H. Tawbi

392 views

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

413 views

ESMO 2024 Summary: Metastatic Melanoma Highlights

2024 ESMO Annual Meeting Insights Hub

C. Blank

197 views

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Vanderbilt University Medical Center (VUMC)

D. Johnson

400 views

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

2024 ASCO® Annual Meeting Insights Hub

A. Hauschild

527 views

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

326 views

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We Been a…

2024 ASCO® Annual Meeting Insights Hub

P. Corrie

289 views

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

2024 ESMO Annual Meeting Insights Hub

D. Johnson

178 views

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

2024 ASCO® Annual Meeting Insights Hub

C. Blank

263 views

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

534 views

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

240 views

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunotherapy - Pre-op, Post-op or No-op? NADINA Trial Discussion"

Overview & NADINA Trial Introduction

Neoadjuvant vs. Adjuvant Therapy Comparison

Event-Free Survival & Treatment Rationale

Adjuvant Therapy Evolution & Current Options

Immune-Related Adverse Events & Quality of Life

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical Outcomes…

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

Recommended

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Advances in the Treatment of Melanoma

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

ASCO® 2024 Summary: "Insights in Melanoma"

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcome…

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

ESMO 2024 Summary: Metastatic Melanoma Highlights

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in St…

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We Been a…

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macro…

Developmental Therapeutics Highlights From ASCO® 2024

ESMO 2024 Summary: Developmental Therapeutics Highlights